Sharing knowledge to improve scientific exchange in UK drug discovery
ELRIG UK and British Pharmacological Society initiate a 2-year strategic alliance.
The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society have formed a strategic alliance. The 2-year agreement offers the organisations the opportunity to benefit from each other’s scientific communities to help strengthen their positions and reach.
Members of ELRIG UK and the British Pharmacological Society will gain access to new openings for scientific exchange and collaboration between industry, academia and the clinic to help drive the successful discovery and development of new medicines across the UK.
The two groups work in complementary sectors of the UK pharmaceutical and biotech industries, academia and clinical pharmacology. The alliance creates a framework for joint working on a variety of activities that will support both communities, encouraging a multidisciplinary approach that better facilitates the exchange of ideas and information. ELRIG UK and the British Pharmacological Society have committed to hosting joint and complementary meetings. The alliance also offers both groups a wider reach, to help grow their audiences, and create exciting new opportunities for early career professionals’ education and training.
ELRIG UK’s mission is to provide leading-edge knowledge to the life sciences community on an open access basis, via a programme of scientific meetings and events. The British Pharmacological Society promotes and advances pharmacology by hosting conferences, publishing peer-reviewed journals and supporting the development of educational materials and policy proposals.
Steve Rees, Chairman of ELRIG UK, and VP of Discovery Biology at AstraZeneca, said: “The strategic alliance with the British Pharmacological Society formalises a joint goal of growth in the industrial and academic segments, and recognises the harmonies between our organisations. Joining forces will help us improve education, networking and other services available to our communities, allowing us to become more impactful advocates for the life sciences industry.”
Professor Steve Hill, President of the British Pharmacological Society, and Professor of Molecular Pharmacology at the University of Nottingham, added: “We recognise that modern drug discovery is a multistakeholder process, and that professionals are likely to move between sectors throughout the course of their working lives. It therefore makes sense for our programmes to represent all facets of drug discovery, and we look forward to working with ELRIG UK to help achieve this goal.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance